2013/01 - Galactosaminogalactan comprising alpha 1-4 linked galactose and alpha 1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease

Titolo brevetto
Galactosaminogalactan comprising alpha 1-4 linked galactose and alpha 1-4 linked N-acetylgalactosamine for use in the treatment of at least one inflammatory disease
Stato
Abbandonato
Numero domanda di priorità
EP 13305034.4 - a nome dell'Institut Pasteur
Data di priorità
2013-01-14 00:00:00
Fase
EUROPA, esteso a PCT
Dipartimento
Dipartimento di medicina sperimentale
Autori
Luigina Romani, Antonella De Luca, Silvia Bozza, Jean Paul Latgé; Thierry Fontaine, F. van de Veerdonck, L. Joosten, M. Gresnigt, M. Netea
Co-titolari
INSTITUT PASTEUR (46%) - Università degli Studi di Perugia (25%) - RADBOUD UNIVERSITY NIJMEGEN (29%)
Descrizione

A first object of the invention is galactosaminogalactan comprising [alpha]1-4 linked galactose, [alpha]1-4 linked N-acetylgalactosamine, and optionally [alpha]1-4 linked galactosamine, for use in the treatment of at least one inflammatory disease. Another object of the invention is a pharmaceutical composition comprising a galactosaminogalactan comprising [alpha]1-4 linked galactose, [alpha]1-4 linked N-acetylgalactosamine, and optionally [alpha]1-4 linked galactosamine, as defined herein, and optionally a pharmaceutically acceptable carrier. Another object of the invention is a pharmaceutical composition according to the invention, for use in the treatment of at least one inflammatory disease. Another object of the invention is an inhibitor of IL-1RA for use in the treatment of human fungal diseases. Another object of the invention is a pharmaceutical composition comprising an inhibitor of IL-1RA, and optionally a pharmaceutically acceptable carrier.

Contatto
ufficio.ilo@unipg.it

Torna all'elenco

Condividi su